Dr. Reddy's Laboratories

Overview

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. Founded in 1984, Dr. Reddy's is one of India's largest pharmaceutical companies with a significant global presence, particularly in generic medications, active pharmaceutical ingredients (APIs), and proprietary products. The company has developed a substantial portfolio of generic central nervous system (CNS) medications[@dr2026].

Company Overview

| Attribute | Value |
|-----------|-------|
| Founded | 1984 |
| Headquarters | Hyderabad, India |
| NSE | DRREDDY |
| BSE | 500078 |
| Market Cap | ~$10 billion (2026) |
| Revenue | ~$3 billion (FY2025) |
| Employees | ~22,000 |

Therapeutic Focus

Neurology

Dr. Reddy's has a comprehensive portfolio of generic neurology medications:

| Category | Products | Notes |
|----------|----------|-------|
| Parkinson's Disease | Levodopa, Carbidopa, Entacapone | Generic combinations |
| Epilepsy | Valproic acid, Carbamazepine, Lamotrigine | First-line generics |
| Stroke | Aspirin, Clopidogrel | Antiplatelet agents |
| Migraine | Sumatriptan, Rizatriptan | Acute treatment |

Psychiatry

| Category | Products | Notes |
|----------|----------|-------|
| Depression | Escitalopram, Sertraline, Venlafaxine | SSRIs and SNRIs |
| Schizophrenia | Risperidone, Olanzapine, Quetiapine | Atypical antipsychotics |
| Anxiety | Lorazepam, Clonazepam | Benzodiazepines |
| Bipolar Disorder | Lithium, Valproate | Mood stabilizers |

Pain Management

Overview

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. Founded in 1984, Dr. Reddy's is one of India's largest pharmaceutical companies with a significant global presence, particularly in generic medications, active pharmaceutical ingredients (APIs), and proprietary products. The company has developed a substantial portfolio of generic central nervous system (CNS) medications[@dr2026].

Company Overview

| Attribute | Value |
|-----------|-------|
| Founded | 1984 |
| Headquarters | Hyderabad, India |
| NSE | DRREDDY |
| BSE | 500078 |
| Market Cap | ~$10 billion (2026) |
| Revenue | ~$3 billion (FY2025) |
| Employees | ~22,000 |

Therapeutic Focus

Neurology

Dr. Reddy's has a comprehensive portfolio of generic neurology medications:

| Category | Products | Notes |
|----------|----------|-------|
| Parkinson's Disease | Levodopa, Carbidopa, Entacapone | Generic combinations |
| Epilepsy | Valproic acid, Carbamazepine, Lamotrigine | First-line generics |
| Stroke | Aspirin, Clopidogrel | Antiplatelet agents |
| Migraine | Sumatriptan, Rizatriptan | Acute treatment |

Psychiatry

| Category | Products | Notes |
|----------|----------|-------|
| Depression | Escitalopram, Sertraline, Venlafaxine | SSRIs and SNRIs |
| Schizophrenia | Risperidone, Olanzapine, Quetiapine | Atypical antipsychotics |
| Anxiety | Lorazepam, Clonazepam | Benzodiazepines |
| Bipolar Disorder | Lithium, Valproate | Mood stabilizers |

Pain Management

| Category | Products | Notes |
|----------|----------|-------|
| Neuropathic Pain | Gabapentin, Pregabalin | First-line generics |
| Acute Pain | Tramadol, Diclofenac | NSAIDs and opioids |
| Chronic Pain | Amitriptyline, Nortriptyline | TCAs |

Research Pipeline

Proprietary Products

Dr. Reddy's invests in proprietary drug development:

| Product | Mechanism | Stage | Indication |
|---------|-----------|-------|------------|
| DRR-001 | Novel analgesic | Phase 1 | Chronic pain |
| DRR-02 | CNS modulator | Discovery | Depression |

Generic Pipeline

• 30+ generic drug applications pending approval
• Focus on complex generics and specialty products
• Biosimilar development in early stages

Global Markets

United States

• Fifth-largest generic pharmaceutical company in the US
• Strong portfolio of 100+ approved products
• Focus on complex generics with limited competition

Europe

• Growing presence through acquisitions
• Generic product launches in key markets
• Strategic partnerships with European distributors

Emerging Markets

• Strong position in Asia-Pacific, Africa, and Latin America
• Branded generics business in India
• Expanded reach through strategic partnerships

Manufacturing

Dr. Reddy's operates multiple manufacturing facilities:

| Location | Focus |
|----------|-------|
| Hyderabad, India | API and formulations |
| Visakhapatnam, India | API manufacturing |
| Mysore, India | Biologics |
| US (New Jersey) | Packaging and distribution |

Strategic Initiatives

Financial Highlights

• FY2025 Revenue: ₹27,000 crore (~ billion)
• R&D Investment: ~8% of revenue
• US ANDA Approvals: 15+ in FY2025
• [Indian Pharmaceutical Companies](/genes/ar)
• Generic Drug Manufacturers
• [Parkinson's Disease Treatments](/genes/ar)
• [Alzheimer's Disease Treatments](/genes/atm)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References